-
More Than 30% Upside Seen For Vertex Stock On The Heels Of Phase 2 Data
Wednesday, July 19, 2017 - 9:45am | 348Read More...Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)'s stock soared 25 percent after the company reported encouraging phase 2 data. The company's three-drug cocktails showed an improvement in lung function among patients with cystic fibrosis by 9.6 percentage points or more, which was better...
-
Janney Initiates Galapagos At Buy, Sees Fair Value Of Shares At $64
Tuesday, August 30, 2016 - 12:16pm | 552Read More...Janney has initiated coverage of Galapagos NV (ADR) (NASDAQ: GLPG) with a Buy rating and fair value estimate of $64, citing potential success of Filgotinib. Galapagos has deals with Gilead Sciences, Inc. (NASDAQ: GILD) and AbbVie Inc (NYSE: ABBV) for the development of Filgotinib in inflammatory...
-
JPMorgan, Canaccord Confident That Vertex's CF Drug Will Get FDA Approval
Wednesday, May 13, 2015 - 1:55pm | 781Read More...On May 12, the FDA advisory committee recommended that the FDA approve Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) Orkambi therapy to treat cystic fibrosis. Shares of Vertex increased nearly 8 percent in pre-market trading following the announcement. The FDA advisory committee provides...
-
Is Gilead Sciences About To Buy Vertex For $45 Billion?
Thursday, April 30, 2015 - 11:57am | 498Read More...Gilead Sciences, Inc. (NASDAQ: GILD) has been rolling in the money since the release of its hepatitis C drug duo, Sovaldi and Harvoni. Now investors are wondering how Gilead will put its pile of cash to work. In its Q4 earnings report, Gilead announced that its cash position had increased from...
-
Gilead-Vertex Deal Has 'Low Probability' Of Happening, RBC Capital Says
Tuesday, April 21, 2015 - 12:57pm | 346Read More...In a report published Tuesday, RBC Capital Markets analyst Michael Yee commented on the increasing Street "appreciation" over the idea that Gilead Sciences, Inc. (NASDAQ: GILD) should acquire Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX). Yee noted that many investors are working...
-
Short Interest in Biotech Firms on the Rise
Monday, August 27, 2012 - 3:21pm | 571Read More...Short interest data has been released from the August 15 settlement date. Overall short sellers have continued to bet on biotech firms compared to the July 31 settlement date. A couple of notable exceptions are Alexion Pharmaceuticals (NASDAQ: ALXN) and Biogen Idec (NASDAQ: BIIB), which saw short...
-
UPDATE: Citadel Securities Initiates Coverage on Vertex
Monday, August 8, 2011 - 7:04am | 85Read More...Citadel Securities has published a report on Vertex (NASDAQ: VRTX) initiating coverage on the medicine developer. In the report, Citadel Securities wrote, "We are initiating coverage of Vertex Pharmaceuticals (VRTX) with a Neutral rating and $46 price target. While the launch of Incivek for HCV is...
-
Street Overestimating Sales of Vertex's Incivek, Morgan Stanley Reports
Thursday, June 23, 2011 - 7:35am | 48Read More...Morgan Stanley believes the Street is overestimating the sales growth trajectory of Vertex's (NASDAQ: VRTX) “novel hepatitis C (HCV) therapy, Incivek.” “We expect numbers to disappoint, especially in the early quarters of launch,” Morgan Stanley writes. Vertex closed Wednesday at $47.21.
-
Oppenheimer's Current Biotech Ratings
Monday, September 13, 2010 - 10:41am | 138Read More...Stock Prices as of September 10, 2010 Anadys Pharmaceuticals Inc. (NASDAQ: ANDS) $1.75, PERFORM BioMarin Pharmaceutical (NASDAQ: BMRN) $22.62, PERFORM Chelsea Therapeutics (NASDAQ: CHTP) $3.91, PERFORM Dynavax Technologies (NASDAQ: DVAX) $1.69, PERFORM Genzyme (NASDAQ: GENZ) $70.63, PERFORM...
